Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. - Wikidata - awgldk - TriplyDB

Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load.

Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load.

http://www.wikidata.org/entity/Q37346823

about

Efficacy and safety of tenofovir in chronic hepatitis B: Australian real world experience Differential binding of tenofovir and adefovir to reverse transcriptase of hepatitis B virus Deep sequencing analysis of HBV genotype shift and correlation with antiviral efficiency during adefovir dipivoxil therapy Cost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in China Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort.Efficacy and Safety of Tenofovir Disoproxil Treatment for Chronic Hepatitis B Patients with Genotypic Resistance to Other Nucleoside Analogues: A Prospective Study.Optimization therapy for the treatment of chronic hepatitis B Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma.Liver fibrosis regression and progression during controlled hepatitis B virus infection among HIV-HBV patients treated with tenofovir disoproxil fumarate in France: a prospective cohort study.Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir.Prevalence of hepatitis B and delta according to HIV-type: a multi-country cross-sectional survey in West Africa Clinical Relevance of Minimal Residual Viremia during Long-Term Therapy with Nucleos(t)ide Analogues in Patients with Chronic Hepatitis B.Antiviral therapies and prospects for a cure of chronic hepatitis B.Similar efficacy and safety of tenofovir in Asians and non-Asians with chronic hepatitis B.Efficacy of tenofovir disoproxil fumarate therapy in nucleoside-analogue naive Iranian patients treated for chronic hepatitis B.Virologic response and safety of tenofovir versus entecavir in treatment-naïve chronic Hepatitis B patients Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B Tenofovir in treatment of Iranian patients with chronic hepatitis B virus infection: An open-label case series.Predictive Value of Antiviral Effects in the Development of Hepatocellular Carcinoma in the General Korean Population with Chronic Hepatitis B Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA.Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir.A meta-analysis comparing the efficacy of entecavir and tenofovir for the treatment of chronic hepatitis B infection.Recent advances in prevention of hepatitis B recurrence after liver transplantation.Current treatment of hepatitis B virus infections.Long-term progression of viral load and serum markers of fibrosis among treated and untreated patients with chronic hepatitis B.Week 4 viral load predicts long-term suppression of hepatitis B virus DNA during antiviral therapy: improving hepatitis B treatment in the real world.Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment.Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs.No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment.Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy Outcomes in HIV/HBV-Coinfected Patients in the Tenofovir Era Are Greatly Affected by Immune Suppression.Efficacy and safety of tenofovir in nucleos(t)ide-naïve patients with genotype C chronic hepatitis B in real-life practice.Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial.Efficacy of tenofovir switch therapy for nucleos(t)ide-experienced patients with chronic hepatitis B.Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/ml).Use of hepatitis B surface and "e" antigen quantification during extensive treatment with tenofovir in patients co-infected with HIV-HBV.Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment.Oral antiviral therapy for hepatitis B: the case of besifovir, a new kid on the block with a long way to go.No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B.

P2860

Q28468387-4E743BBA-0B25-405F-BB93-E167E0968275 Q28542705-0CE3E371-305C-4FBF-AA07-A34275DDD69D Q28545779-637F9772-E04C-4358-A993-4BD48FE2BC63 Q28550643-2B2FB068-AE46-488C-A299-7B3C0D429B4D Q30391932-408B1BE9-8AE8-4B17-B8C3-4F1AEF4DAC79 Q30860824-23DCF2C3-42A1-4AFE-A5AF-44457EEA3CE4 Q33608997-58366AFE-1562-4902-96FF-C78FE50EEF7F Q33626813-E22DD644-1624-4048-ADBE-52FA52F67194 Q33723810-B16EC7F4-33D4-4395-B2FE-59FABF600E7E Q33787655-F94F487B-5C24-48DD-BC87-BCA813D344E5 Q33857643-AD2B1E65-4EA4-4D25-A838-77DB629605F2 Q33869423-B00C48EB-CA98-4D13-9C82-69FE4D7AD801 Q34797281-1B379261-7DA6-4388-B0CE-0392A3925399 Q35245231-CF45E553-EEEB-4E2F-B290-CE84021589CF Q35594210-91D9E273-2332-44AC-A216-956FCB8A70E7 Q35671645-A4D4E2A5-99E0-4B4F-96F4-C3E2295B78A7 Q35681979-798594D8-16E2-4980-AB75-51665B0B3B15 Q36779207-D53DC7D8-4E57-4B37-A3C2-F8149B762158 Q37137734-07F0B6A1-DB01-4287-8222-E0EFB98EF49F Q37381790-9A13CC8D-D4CC-4417-BDC4-7799953A9257 Q37722853-69A63B8A-FBEE-4F7C-A864-B8AFDEBACC8C Q38223361-9F62D096-A2CE-4253-B74B-C35FDC2DB173 Q38257890-70AD8008-5FFF-4638-9E8A-885E78F05A26 Q38333875-CDDE4791-1619-4574-A574-14AFDFC115EE Q38553056-476CE3C1-12EE-4B21-9730-FC60F18EDB25 Q39152779-B381D67A-27A6-4E62-BAD7-808B867A5570 Q39443390-AF301382-9C7C-4948-A186-348248AE9F6B Q40409098-EE1F12A8-BBE7-4EA7-AE07-C18130D5292B Q40555175-36F13288-BB7B-4FC6-845A-61B947DA7D72 Q40569855-5ECFF0C3-4A9E-4C21-A3AD-ACFEE386F8D4 Q40676324-815EF32A-F884-4641-A98B-53D6E6A2E51F Q41208197-DB463D87-3C91-4AB4-B721-0BDD7B86250E Q41367567-2965B133-6598-4F89-ABF7-5FDC62DB24DD Q41730783-26E9AB5E-50D9-4A40-AC48-142207694377 Q42151600-CF344097-98E7-48BF-AC69-84EB27CA5057 Q42184918-8272FD1C-4F85-46D7-AFF7-9942D8808740 Q42233095-51F9DC15-C944-42E5-84FE-E871DED6390D Q42249938-BD66E45E-56E9-47B8-BD83-D76BAB8AA749 Q42259582-E74EAB09-50C7-486D-B4A6-6FEFEEE25C90 Q42277100-207586A6-B3E2-4ACD-8284-B7F49A78FAD9

P2860

Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load.

http://www.wikidata.org/entity/Q37346823

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 03 May 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Efficacy of tenofovir disoprox ...... with high baseline viral load.

@en

Efficacy of tenofovir disoprox ...... with high baseline viral load.

@nl

type

label

Efficacy of tenofovir disoprox ...... with high baseline viral load.

@en

Efficacy of tenofovir disoprox ...... with high baseline viral load.

@nl

prefLabel

Efficacy of tenofovir disoprox ...... with high baseline viral load.

@en

Efficacy of tenofovir disoprox ...... with high baseline viral load.

@nl

P1433

Q37346823-575098B4-869A-4844-8627-BFE7350BE05A

P1476

Q37346823-47E29C5C-5125-4D9E-9D51-55E8FA85D068

P2093

Q37346823-024167DD-23A0-4CC5-A2FF-B843A8FDA993

Q37346823-35BC0623-899F-40B6-893D-C7A66470ACA4

Q37346823-4CEAB02A-C3B1-4E20-9522-F4BCDA7D2146

Q37346823-5C1CFF64-7D94-4673-A656-0168D33E4318

Q37346823-667D3D74-A475-4DEC-9278-422DEFB0CA0C

Q37346823-73CD0AD3-9A48-4E80-A5D9-F18AC9D4AA99

Q37346823-874420FB-0A76-4AB0-A9CE-275BF1856C2B

Q37346823-877ABD53-4B10-42A6-B617-761E7EBF6C54

Q37346823-9C49A9F8-16CF-42A0-9132-9E6B6FEF3FB6

Q37346823-E097C104-9CC1-405B-851B-35624F323940

P2860

Q37346823-01E22C0A-53D2-4615-BDD3-7439EEFB406F

Q37346823-10BADEDA-27D7-49DC-8E1E-F6B126EAE497

Q37346823-13A7E50D-1076-4998-A115-BFCB8B1AFD5C

Q37346823-5AC6CF3A-6070-4059-AFDF-80C2552D4E4B

Q37346823-5ADCC7B2-DF5C-479F-8040-200FAE2E701A

Q37346823-5CDA4789-DC49-4622-B5CC-5D353FC365C8

Q37346823-65E8DAB8-2769-4170-9FCD-4A1E068511E7

Q37346823-7A928DFB-EF94-44BD-8B35-ECD7EBF57466

Q37346823-8118B4E7-6FDB-461B-9314-D9587FEDF5E1

Q37346823-9B3BD36B-9BC4-4C77-AF3A-36170C334269

P304

Q37346823-A7DF55B9-EA20-41F2-90B4-A988C4A20755

P31

Q37346823-DD360708-0380-4D80-87D0-9FE05658F166

P356

Q37346823-84D2A2EA-27E4-492B-A8A2-B67A1B0F3D42

P407

Q37346823-DCAA8C02-9DFD-43FC-89E0-EFA401C28458

P433

Q37346823-330EBCE5-2C33-47C9-8534-03E0FDEFBD42

P478

Q37346823-3545CC24-30E0-4926-93E3-AFD6EFC3D544

P577

Q37346823-9E216CAE-14BE-4069-8759-9AFDF58E72BE

P5875

Q37346823-79389738-2A5A-49CA-9664-3FB2FF6C14C2

P698

Q37346823-88FA825D-5D35-4684-9479-1DEDBB453A2D

P921

Q37346823-984ABCF7-3849-4FBD-8E7A-0829D2E9E738

Q37346823-CF472177-9E97-4323-BE55-22526953128B

P932

Q37346823-037BE409-D3D5-4F50-A5CA-CC91B6E37FCC

P356

P1433

P1476

Efficacy of tenofovir disoprox ...... with high baseline viral load.

@en

P2093

Andrzej Horban

http://www.w3.org/2001/XMLSchema#string

Eduardo B Martins

http://www.w3.org/2001/XMLSchema#string

Jan Sperl

http://www.w3.org/2001/XMLSchema#string

John F Flaherty

http://www.w3.org/2001/XMLSchema#string

Jörg Petersen

http://www.w3.org/2001/XMLSchema#string

Kathryn M Kitrinos

http://www.w3.org/2001/XMLSchema#string

Leland J Yee

http://www.w3.org/2001/XMLSchema#string

Patrick Marcellin

http://www.w3.org/2001/XMLSchema#string

Phillip Dinh

http://www.w3.org/2001/XMLSchema#string

Stuart C Gordon

http://www.w3.org/2001/XMLSchema#string

P2860

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.

Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

Treatment of chronic hepatitis B: Evolution over two decades.

Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.

HBV DNA replication mediated by cloned patient HBV reverse transcriptase genes from HBV genotypes A-H and its use in antiviral phenotyping assays.

No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus.

Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage.

Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.

Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy.

P304

505-513

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.26277

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235386102

http://www.w3.org/2001/XMLSchema#string

P698

23364953

http://www.w3.org/2001/XMLSchema#string

P921

P932

3842114

http://www.w3.org/2001/XMLSchema#string